scholarly journals Clinical results of proton beam therapy for twenty older patients with esophageal cancer

2015 ◽  
Vol 49 (4) ◽  
pp. 371-378 ◽  
Author(s):  
Takashi Ono ◽  
Tatsuya Nakamura ◽  
Yusuke Azami ◽  
Hisashi Yamaguchi ◽  
Yuichiro Hayashi ◽  
...  
Keyword(s):  
Esophageal Cancer ◽  
Proton Beam ◽  
Older Patients ◽  
Dose Range ◽  
Proton Beam Therapy ◽  
Clinical Results ◽  
Local Control Rate ◽  
High Dose ◽  
X Ray ◽  
Node Metastases

Abstract Background. In an aging society, increasing number of older patients are diagnosed with esophageal cancer. The purpose of this study was to assess the clinical efficacy and safety of proton beam therapy for older patients with esophageal cancer. Patients and methods. Older patients (age: ≥ 65 years) newly diagnosed with esophageal cancer between January 2009 and June 2013 were enrolled in this study. All patients underwent either proton beam therapy alone or proton beam therapy with initial X-ray irradiation. Toxicities were evaluated using the Common Terminology Criteria for Adverse Events version 4.0. Results. Twenty patients were eligible for this study and all completed the treatment. The median age was 78 years (range: 65–89 years) and the median follow-up time was 26.5 months (range: 6–62 months). Seven patients had lymph node metastases and 10 had stage II/III cancer. The median dose of proton beam therapy was 72.6 Gy relative biological dose effectiveness (RBE) (range: 66–74.8 Gy [RBE]) for proton beam therapy alone and 33 Gy (RBE) (range: 30.8–39.6 Gy [RBE]; total dose range: 66.8–75.6 Gy [RBE]) for proton beam therapy with initial X-ray irradiation. The 2-year overall survival rate was 81.8% (95% confidence interval [CI]: 62.4%–100%), and the 2-year local control rate was 89.4% (95% CI: 75.5%–100%). Grade 2 or 3 toxicities occurred in some cases; however, no grade 4 or 5 toxicity was observed. Conclusions. High-dose (66–75.6 Gy [RBE]) proton beam therapy without chemotherapy was an efficacious and safe treatment for older patients with esophageal cancer.

scholarly journals Clinical Results of Proton Beam Therapy for Esophageal Cancer: Multicenter Retrospective Study in Japan

Cancers ◽  
2019 ◽  
Vol 11 (7) ◽  
pp. 993 ◽  
Author(s):  
Ono ◽  
Wada ◽  
Ishikawa ◽  
Tamamura ◽  
Tokumaru
Keyword(s):  
Esophageal Cancer ◽  
Proton Beam ◽  
Large Population ◽  
Cancer Control ◽  
Proton Beam Therapy ◽  
Clinical Results ◽  
Local Control Rate ◽  
Newly Diagnosed ◽  
Inclusion Criteria ◽  
Photon Radiotherapy

There are few reports about the clinical results of proton beam therapy for esophageal cancer in a large population. The purpose of this study was to evaluate the clinical results of proton beam therapy for esophageal cancer in a large population using a multicentered database. Between January 2009 and December 2013, patients newly diagnosed with esophageal cancer and who had received proton beam therapy were retrospectively recruited from a database of four proton beam therapy centers in Japan. Two hundred and two patients (including 90 inoperable patients) fulfilled the inclusion criteria, and 100 patients (49.5%) had stage III/IV cancer (Union for International Cancer Control 8th). The 3-year and 5-year overall survival rate was 66.7% and 56.3%, respectively. The five-year local control rate was 64.4%. There were two patients with grade three pericardial effusion (1%) and a patient with grade three pneumonia (0.5%). No grade 4 or higher cardiopulmonary toxicities were observed (Common Terminology Criteria for Adverse Events version 4.0). This study suggests that proton beam therapy for esophageal cancer was not inferior in efficacy and had lower rates of toxicities in comparison to photon radiotherapy. Therefore, proton beam therapy can serve as an alternate treatment for patients with esophageal cancer.

Clinical Results of Proton-Beam Therapy for Locoregionally Advanced Esophageal Cancer

2010 ◽  
Vol 186 (9) ◽  
pp. 482-488 ◽  
Author(s):  
Masashi Mizumoto ◽  
Shinji Sugahara ◽  
Hidetsugu Nakayama ◽  
Haruko Hashii ◽  
Akira Nakahara ◽  
...  
Keyword(s):  
Esophageal Cancer ◽  
Proton Beam ◽  
Proton Beam Therapy ◽  
Clinical Results ◽  
Advanced Esophageal Cancer

Clinical Results of Proton Beam Therapy for Esophageal Cancer at the University of Tsukuba

2005 ◽  
Vol 63 ◽  
pp. S163-S164
Author(s):  
S. Sugahara ◽  
K. Tokuuye ◽  
A. Nakahara ◽  
H. Igaki ◽  
M. Hata ◽  
...  
Keyword(s):  
Esophageal Cancer ◽  
Proton Beam ◽  
Proton Beam Therapy ◽  
Clinical Results ◽  
The University

Improving Outcomes for Esophageal Cancer using Proton Beam Therapy

2016 ◽  
Vol 95 (1) ◽  
pp. 488-497 ◽  
Author(s):  
Michael D. Chuong ◽  
Christopher L. Hallemeier ◽  
Salma K. Jabbour ◽  
Jen Yu ◽  
Shahed Badiyan ◽  
...  
Keyword(s):  
Esophageal Cancer ◽  
Proton Beam ◽  
Proton Beam Therapy

scholarly journals A novel range telescope concept for proton CT

2022 ◽  
Author(s):  
Marc Granado-González ◽  
César Jesús-Valls ◽  
Thorsten Lux ◽  
Tony Price ◽  
Federico Sánchez
Keyword(s):  
Computed Tomography ◽  
Proton Beam ◽  
Energy Resolution ◽  
Plastic Scintillator ◽  
Proton Beam Therapy ◽  
Stopping Power ◽  
High Quality ◽  
X Ray ◽  
Proton Computed Tomography ◽  
Clinical Conditions

Abstract Proton beam therapy can potentially offer improved treatment for cancers of the head and neck and in paediatric patients. There has been asharp uptake of proton beam therapy in recent years as improved delivery techniques and patient benefits are observed. However, treatments are currently planned using conventional x-ray CT images due to the absence of devices able to perform high quality proton computed tomography(pCT) under realistic clinical conditions. A new plastic-scintillator-based range telescope concept, named ASTRA, is proposed here to measure the proton’s energy loss in a pCT system. Simulations conducted using GEANT4 yield an expected energy resolution of 0.7%. If calorimetric information is used the energy resolution could be further improved to about 0.5%. In addition, the ability of ASTRA to track multiple protons simultaneously is presented. Due to its fast components, ASTRA is expected to reach unprecedented data collection rates, similar to 10^8 protons/s.The performance of ASTRA has also been tested by simulating the imaging of phantoms. The results show excellent image contrast and relative stopping power reconstruction.

Computational evaluation of dose distribution for BNCT treatment combined with X-ray therapy or proton beam therapy

2020 ◽  
Vol 165 ◽  
pp. 109295
Author(s):  
Kenta Takada ◽  
Hiroaki Kumada ◽  
Akira Matsumura ◽  
Hideyuki Sakurai ◽  
Takeji Sakae
Keyword(s):  
Proton Beam ◽  
Dose Distribution ◽  
Proton Beam Therapy ◽  
X Ray ◽  
Computational Evaluation

scholarly journals Proton beam therapy: perspectives on the National Health Service England clinical service and research programme

2020 ◽  
Vol 93 (1107) ◽  
pp. 20190873 ◽  
Author(s):  
Neil G Burnet ◽  
Ranald I Mackay ◽  
Ed Smith ◽  
Amy L Chadwick ◽  
Gillian A Whitfield ◽  
...  
Keyword(s):  
Dna Damage ◽  
National Health Service ◽  
Health Service ◽  
Proton Beam ◽  
National Health ◽  
Proton Beam Therapy ◽  
Systematic Evaluation ◽  
High Dose ◽  
X Rays ◽  
The Uk

The UK has an important role in the evaluation of proton beam therapy (PBT) and takes its place on the world stage with the opening of the first National Health Service (NHS) PBT centre in Manchester in 2018, and the second in London coming in 2020. Systematic evaluation of the role of PBT is a key objective. By September 2019, 108 patients had started treatment, 60 paediatric, 19 teenagers and young adults and 29 adults. Obtaining robust outcome data is vital, if we are to understand the strengths and weaknesses of current treatment approaches. This is important in demonstrating when PBT will provide an advantage and when it will not, and in quantifying the magnitude of benefit. The UK also has an important part to play in translational PBT research, and building a research capability has always been the vision. We are perfectly placed to perform translational pre-clinical biological and physical experiments in the dedicated research room in Manchester. The nature of DNA damage from proton irradiation is considerably different from X-rays and this needs to be more fully explored. A better understanding is needed of the relative biological effectiveness (RBE) of protons, especially at the end of the Bragg peak, and of the effects on tumour and normal tissue of PBT combined with conventional chemotherapy, targeted drugs and immunomodulatory agents. These experiments can be enhanced by deterministic mathematical models of the molecular and cellular processes of DNA damage response. The fashion of ultra-high dose rate FLASH irradiation also needs to be explored.

scholarly journals Effectiveness of Proton Beam Therapy on Liver Metastases of Esophageal Cancer: Report of a Case

2015 ◽  
Vol 100 (1) ◽  
pp. 180-184 ◽  
Author(s):  
Hiroto Muroi ◽  
Masanobu Nakajima ◽  
Hitoshi Satomura ◽  
Masakazu Takahashi ◽  
Yasushi Domeki ◽  
...  
Keyword(s):  
Positron Emission Tomography ◽  
Esophageal Cancer ◽  
Lymph Nodes ◽  
Liver Metastases ◽  
Proton Beam ◽  
Primary Tumor ◽  
Proton Beam Therapy ◽  
Emission Tomography ◽  
Mediastinal Lymph Nodes ◽  
Positron Emission

Abstract A 53-year-old man with multiple liver metastasis of esophageal cancer underwent four courses of chemotherapy. After four courses of chemotherapy, positron emission tomography showed progressive disease. Because it was difficult to control the cancer only by chemotherapy, we performed proton beam therapy (PBT) combined with chemotherapy. The irradiated parts were the primary tumor, liver metastases (S2/S4/S6), and mediastinal lymph nodes. The primary tumor including the mediastinal lymph nodes and the S2/S4/S6 metastases received proton beam irradiation at a total dose of 68.2 Gy in 31 fractions and 66.0 Gy in 30 fractions, respectively, according to tumor location. This resulted in a complete response as shown by positron emission tomography. In our experience, PBT exerted a curative effect on liver metastases of esophageal cancer. It is thought that PBT may be effective in the treatment of esophageal cancer. This is the first report about PBT for liver metastases of esophageal cancer.

Sign in / Sign up

Export Citation Format

Share Document